cute monoblastic leukemia (AMoL) (French-American-British (FAB) type M5a), occasionally presents simultaneously with multiple myeloma, other types of plasma cell dyscrasia, non-Hodgkin lymphoma such as chronic lymphocytic leukemia, but there is no report of its presentation with squamous cell lung cancer.
Left CT-guided biopsy of the lung mass provided a histopathological diagnosis of squamous cell lung cancer. Staining for thyroid transcription factor 1 (TTF-1) was negative, staining for p63 was positive, Napsin-A negatif, CK5/6 pozitif. The blood count showed a white cell count 21,530/mm 3 , hemoglobin 7,7g/dl, and platelet count 8,000/mm 3 . Blood chemistry revealed total serum protein 5.4g/dL, albumin 3.3g/dL, alkaline phosphatase 102U/L, AST 12U/L, ALT 33U/L, BUN 32mg/dL, Cr 1mg/dL, LDH 252U/L and uric acid 6.5mg/dL. Coagulation profiles were normal (PT 16.5sec (control from 10 to 15.8 sec) aPTT 30.5sec (control from 26.5 to 40sec)). Because of cytopenia we thought bone marrow infiltration but peripheral blood smear showed markedly increased blasts and decreased platelet count. AMoL is a clinical entity, disseminated intravascular coagulation, hyperleukocytosis and frequently exhibiting extra-medullary involvement, particularly in the skin, gingiva, and central nervous system. 2 Therapeutic results are generally poor due to high rates of fatal complications during induction, induction failures, and frequent extramedullary and medullary relapses. 3 Lung cancer is the leading cause of cancer-related death worldwide. 4 Squamous cell lung cancers account for 20% of all lung cancers. This equates to 350,000 patients diagnosed with this disease worldwide every year. 5 We want to emphasize with this case bone marrow infiltration may not always be a solitary organ tumors infiltration, it may be accompanied by another hematological disease. So, peripheral blood and bone marrow (if necessary) examination should be done in all solitary organ tumors with cytopenia.
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